Improving lipids with prescription icosapent ethyl after previous use of fish oil dietary supplements
Open accessAbstract
Managing dyslipidemia can be challenging in patients with statin intolerance. We describe the lipid effects of icosapent ethyl 4 g/day (high-purity prescription omega-3 eicosapentaenoic acid) in two coronary artery disease patients with statin intolerance who were self-treating with fish oil dietary supplements. After initiating icosapent ethyl, improvements were noted in the first and second patients, respectively, in total cholesterol (-12%; -21%), LDL cholesterol (-3%; -24%), triglycerides (-34%; -16%), non-HDL cholesterol (-12%; -22%), the omega-3 index (+42%; +8%) and eicosapentaenoic acid levels (+275%; +138%). Icosapent ethyl was well tolerated with no adverse events reported. These cases demonstrated favorable lipid effects with prescription icosapent ethyl treatment that may help optimize the care of high-risk coronary artery disease patients with statin intolerance.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Initial data on icosapent ethyl in statin-intolerant patients suggested potential effectiveness.
“The first data on icosapent ethyl (IPE) in patients with statin intolerance suggested that it was potentially effective in this group of patients (143).”
From The Role of Nutraceuticals in Statin Intolerant Patients (2018) · cites this paper as [143]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081 · see citing works
Heart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., de Ferranti, S., Després, J.-P., Fullerton, H. J., Howard, V. J., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000152 · Cited by 5,797 · see citing works
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487 · see citing works
Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516 · see citing works
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296 · see citing works
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871 · see citing works
Omega-3 Fatty Acids and Cardiovascular Disease
Mozaffarian, D., & Wu, J. H. Y. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.063 · Cited by 1,771 · see citing works
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.013 · Cited by 1,560 · see citing works
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509 · see citing works
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 772 · see citing works
Why US adults use dietary supplements
Bailey, R. L., Gahche, J. J., Miller, P. E., Thomas, P. R., & Dwyer, J. T. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2299 · Cited by 745 · see citing works
High Ratio of Triglycerides to HDL-Cholesterol Predicts Extensive Coronary Disease
da Luz, P. L., Favarato, D., Faria‐Neto, J. R., Lemos, P. A., & Chagas, A. C. P. (2008) · Clinics · doi:10.1590/s1807-59322008000400003 · Cited by 385 · see citing works
Bays, H. E., Ballantyne, C. M., Kastelein, J. J., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.04.015 · Cited by 358 · see citing works
Ballantyne, C. M., Bays, H. E., Kastelein, J. J., Stein, E., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.05.031 · Cited by 342 · see citing works
Grundy, S. M., Arai, H., Barter, P. J., Bersot, T. P., Betteridge, D. J., Carmena, R., Cuevas, A. M., Davidson, M. H., Genest, J. J., Kesäniemi, Y. A., et al. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.12.005 · Cited by 328 · see citing works
Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA
Albert, B. B., Derraik, J. G. B., Cameron-Smith, D., Hofman, P. L., Tumanov, S., Villas-Boas, S. G., Garg, M. L., & Cutfield, W. S. (2015) · Scientific Reports · doi:10.1038/srep07928 · Cited by 238 · see citing works
Borow, K. M., Nelson, J. R., & Mason, R. P. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.035 · Cited by 175 · see citing works
Quispe, R., Manalac, R. J., Faridi, K. F., Blaha, M. J., Toth, P. P., Kulkarni, K. R., Nasir, K., Virani, S. S., Banach, M., Blumenthal, R. S., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.057 · Cited by 172 · see citing works
Oxidation of Marine Omega-3 Supplements and Human Health
Albert, B. B., Cameron‐Smith, D., Hofman, P. L., & Cutfield, W. S. (2013) · BioMed Research International · doi:10.1155/2013/464921 · Cited by 164 · see citing works
Matsuzaki, M., Yokoyama, M., Saitō, Y., Origasa, H., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., Kita, T., et al. (2009) · Circulation Journal · doi:10.1253/circj.cj-08-1197 · Cited by 157 · see citing works
Omega-3 Index and Cardiovascular Health
von Schacky, C. (2014) · Nutrients · doi:10.3390/nu6020799 · Cited by 155 · see citing works
Hazards of Hindsight — Monitoring the Safety of Nutritional Supplements
Cohen, P. A. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1315559 · Cited by 149 · see citing works
Bays, H. E., Ballantyne, C. M., Braeckman, R. A., Stirtan, W. G., & Soni, P. N. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-012-0002-3 · Cited by 141 · see citing works
Overview of omega-3 Fatty Acid therapies.
Bradberry, J. C., & Hilleman, D. E. (2013) · PubMed Central · Cited by 109 · see citing works
van Wijk, D. F., Sjouke, B., Figueroa, A. L., Emami, H., van der Valk, F. M., MacNabb, M. H., Hemphill, L., Schulte, D. M., Koopman, M. G., Lobatto, M. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.088 · Cited by 105 · see citing works
Bays, H. E., Braeckman, R. A., Ballantyne, C. M., Kastelein, J. J., Otvos, J. D., Stirtan, W. G., & Soni, P. N. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.07.001 · Cited by 94 · see citing works
Kleiner, A. C., Cladis, D. P., & Santerre, C. R. (2015) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.6816 · Cited by 93 · see citing works
Quality analysis of commercial fish oil preparations
Ritter, J. C. S., Budge, S. M., & Jovica, F. (2013) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.5994 · Cited by 85 · see citing works
Overview of Prescription Omega-3 Fatty Acid Products for Hypertriglyceridemia
WEINTRAUB, H. S. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.11.2828 · Cited by 74 · see citing works
Ballantyne, C. M., Braeckman, R. A., Bays, H. E., Kastelein, J. J., Otvos, J. D., Stirtan, W. G., Doyle, R. T., Soni, P. N., & Juliano, R. A. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.11.009 · Cited by 46 · see citing works
Zargar, A., & Ito, M. K. (2011) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2011.0004 · Cited by 39 · see citing works
Prescription Omega-3 Fatty Acid Products and Dietary Supplements Are Not Interchangeable.
Hilleman, D. E., & Smer, A. M. (2016) · PubMed · Cited by 26 · see citing works
Hassan, A., Tajuddin, N. N., & Shaikh, A. (2014) · Cardiology and Therapy · doi:10.1007/s40119-014-0032-9 · Cited by 20 · see citing works
Rupp, T. P., Rupp, K. G., Alter, P., & Rupp, H. (2013) · Cardiology · doi:10.1159/000350656 · Cited by 12 · see citing works
Potential Benefits of Icosapent Ethyl on the Lipid Profile: Case Studies
Hilleman, D. E., & Malesker, M. A. (2014) · Clinical Medicine Insights Cardiology · doi:10.4137/cmc.s13571 · Cited by 11 · see citing works
Castaldo, R. S. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2775 · Cited by 9 · see citing works
Kedia, A. W., & Lynch, E. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1100086 · Cited by 6 · see citing works
Flagged first, then by citations
1 of the 38 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Matsuzaki M, Yokoyama M, Saito Y et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ. J. 73(7), 1283-1290 (2009).
- • Thorough review and comparison of the safety and efficacy of prescription omega-3 products that are approved to date.
Cited by
Sorted by citations
The Role of Nutraceuticals in Statin Intolerant Patients
Banach, M., Patti, A. M., Giglio, R. V., Cicero, A. F. G., Atanasov, A. G., Bajraktari, G., Bruckert, E., Descamps, O., Djuric, D. M., Ezhov, M., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.040 · Cited by 272 · see citing works
Management of Statin Intolerance in 2018: Still More Questions Than Answers
Toth, P. P., Patti, A. M., Giglio, R. V., Nikolić, D., Castellino, G., Rizzo, M., & Banach, M. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0259-7 · Cited by 188 · see citing works
Wierzejska, R. E. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18178897 · Cited by 120 · see citing works
Future perspectives of the pharmacological management of diabetic dyslipidemia
Patti, A. M., Giglio, R. V., Παπάνας, Ν., Rizzo, M., & Rizvi, A. A. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1567328 · Cited by 54 · see citing works
Crandell, J. R., Tartaglia, C., & Tartaglia, J. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1241129 · Cited by 8 · see citing works
- Authors
- Reddy, K. J., & Chowdhury, S.
- Affiliations
- Reddy Cardiac Wellness 3519 Town Center Blvd South Suite A Sugar Land TX 77479 USA
- Amarin (United States) (US)
- Venue
- Future Cardiology
- Publisher
- Informa UK Limited
- Published
- 2016-04-12
- Volume
- 12
- Issue
- 3
- Pages
- 261-268
- ISSN
- 1479-6678 (ISSN-L)
- 1744-8298
- OpenAlex
- W2341160955
- Cited by
- 5
- References
- 38
- Citations by year
- 2021: 1 · 2019: 1 · 2018: 2 · 2016: 1
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Future Cardiology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- icosapent ethyl, eicosapentaenoic acid, statin intolerance, dyslipidemia, coronary artery disease, LDL cholesterol, triglycerides, non-HDL cholesterol, omega-3 index, lipid-lowering therapy
- MeSH terms
- Cholesterol, Humans, Cholesterol, LDL, Male, Middle Aged, Triglycerides, Eicosapentaenoic Acid, Fatty Acids, Omega-3, Dietary Supplements, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
